News
DMAC
1.530
+2.00%
0.030
BRIEF-DiaMedica Therapeutics Announces Full Year 2022 Results
Reuters · 4d ago
DiaMedica Therapeutics Provides A Business Update And Announces FY22 Financial Results; DiaMedica Reported Total Cash, Cash Equivalents And Investments Of $33.5M
Benzinga · 4d ago
DiaMedica Therapeutics GAAP EPS of -$0.52 in-line
Seeking Alpha · 4d ago
Earnings Scheduled For March 28, 2023
Benzinga · 4d ago
Analysts Are Bullish on These Healthcare Stocks: Fennec Pharmaceuticals (FENC), Diamedica Therapeutics (DMAC)
TipRanks · 4d ago
DiaMedica Therapeutics's Earnings Outlook
Benzinga · 5d ago
BRIEF-Diamedica Therapeutics To Report Fourth Quarter 2023 Results
Reuters · 03/20 20:19
FDA clinical holds pick up amid race for risky, innovative medicines – WSJ
Seeking Alpha · 01/10 14:45
Insider Buying: The DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Independent Director Just Bought 38% More Shares
Whilst it may not be a huge deal, we thought it was good to see that the DiaMedica Therapeutics Inc. ( NASDAQ:DMAC...
Simply Wall St. · 12/04/2022 12:04
$1 Million Bet On OmniAb? Check Out These 3 Penny Stocks Insiders Are Buying
Benzinga · 12/02/2022 13:43
DiaMedica Therapeutics GAAP EPS of -$0.12 beats by $0.03
Seekingalpha · 11/09/2022 22:22
DiaMedica Therapeutics Q3 EPS $(0.12) Up From $(0.18) YoY
Benzinga · 11/09/2022 22:09
DiaMedica Therapeutics to Attend the 13th Annual Craig-Hallum Alpha Select Conference November 17, 2022
MINNEAPOLIS, November 07, 2022--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that Rick Pauls, its President and...
Business Wire · 11/07/2022 13:32
DiaMedica Therapeutics to Present at Credit Suisse 31st Annual Healthcare Conference
MINNEAPOLIS, October 31, 2022--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that Rick Pauls, its President and ...
Business Wire · 10/31/2022 12:32
Why Meta Platforms Shares Dipped Around 25%; Here Are 77 Biggest Movers From Yesterday
Benzinga · 10/28/2022 08:57
BRIEF-DiaMedica Therapeutics Says FDA Maintaining Clinical Hold On Remedy2 Trial
Reuters · 10/26/2022 22:31
DiaMedica stock slides 17% after hours as FDA maintains clinical hold on DM199 trial
Seekingalpha · 10/26/2022 20:49
DiaMedica Therapeutics Provides Update on ReMEDy2 Trial
MINNEAPOLIS, October 26, 2022--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today that the Company has received furth...
Business Wire · 10/26/2022 20:30
Insiders rewarded with a US$114k addition on top of their US$676k purchase as DiaMedica Therapeutics Inc. (NASDAQ:DMAC) hits US$41m
DiaMedica Therapeutics Inc. ( NASDAQ:DMAC ) insiders who purchased shares in the last 12 months were richly rewarded...
Simply Wall St. · 10/14/2022 13:49
Why Cyclerion Therapeutics Shares Traded Lower By Around 38%; Here Are 70 Biggest Movers From Yesterday
Gainers Green Giant Inc. (NASDAQ: GGE) jumped 161.1% to close at $1.88 after dipping 29% on Wednesday.
Benzinga · 10/07/2022 10:29
More
Webull provides a variety of real-time DMAC stock news. You can receive the latest news about Diamedica Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About DMAC
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for neurological and kidney diseases, such as acute ischemic stroke (AIS) and chronic kidney disease (CKD). The Company's lead product DM199 mimics the behavior of naturally occurring human kallikrein-1 (KLK1) proteins to preserve and restore circulation to stroke-damaged tissue and improve overall kidney function. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. DM199 therapy has the potential to improve circulation and overall function of critical systems, as well as reduce inflammation and oxidative stress. The Company also has other product pipelines for IgA Nephropathy and African Americans with CKD.